GenAssist
GenAssist is a pre-commercial medical device company developing MyoSponge, an implantable biomaterial scaffold that regenerates skeletal muscle to treat Volumetric Muscle Loss in orthopedic trauma and reconstructive surgery patients at hospitals and surgical centers.
- Company typePrivate
- Founded2019
- HeadquartersSt Louis, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What GenAssist does
GenAssist is a St. Louis, Missouri-based pre-commercial medical-device company founded in 2019 that is developing MyoSponge, an implantable scaffold intended to regenerate functional skeletal muscle in patients suffering from Volumetric Muscle Loss (VML), a condition typically caused by severe orthopedic trauma such as car accidents or gunshot injuries in which dead tissue must be surgically debrided and the body's natural regeneration capacity is overwhelmed. The company targets hospitals and surgical centers performing orthopedic trauma and reconstructive surgery, with surgeons as the end users implanting the device at the point of injury.
MyoSponge is a biomaterial scaffold engineered to mimic the Basal Lamina, the native extracellular support structure that enables muscle-cell growth. The platform architecture allows patient-resident stem cells to migrate into the scaffold, proliferate, and mature into new muscle fibers, after which the scaffold gradually resorbs and is replaced by endogenous functional tissue. Core intellectual property is protected by granted US Patent 11,744,922 B2, and preclinical validation in an NSF SBIR-funded large-animal pig model of VML demonstrated a 46% improvement in muscle strength, 27% more muscle mass, and 75% more muscle fibers. Ongoing discovery work is conducted in partnership with Saint Louis University's Musculoskeletal Tissue Engineering Laboratory, where the technology was originally invented.
GenAssist operates a B2B enterprise sales motion that is currently in pre-revenue formation. Revenue, once generated, is expected to flow from one-time medical-device sales of MyoSponge to hospitals and surgical centers, priced via quotation-based B2B contracts. The company is pre-commercial, with awareness driven primarily by scientific publications, conference presence, and direct inquiries through its website. To date the company has raised modest non-dilutive and corporate capital (including a $295,000 NSF SBIR Phase I award in 2023, Arch Grants funding in 2025, and equity-style checks from Baxter, Endeavor Health, and Hologic) and operates with a 1–10 person founder-led team (CEO Joe Beggs, CTO Gabe Haas, Chief Discovery Officer Dr. Koyal Garg, and Senior Scientist Dr. Deepa Patil).
GenAssist firmographics
Firmographics- Name
- GenAssist
- Legal name
- GenAssist
- Website
- https://genassist.co
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- GenAssist is a pre-commercial medical device company developing MyoSponge, an implantable biomaterial scaffold that regenerates skeletal muscle to treat Volumetric Muscle Loss in orthopedic trauma and reconstructive surgery patients at hospitals and surgical centers.
- Ownership category
- akta.pro rank
GenAssist industry classification
Industry- Product category
- Regenerative Medicine Implants
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)
- akta.pro secondary industry
- Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)
Keywords
Where GenAssist is headquartered
LocationHeadquarters
- HQ city
- St Louis
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
GenAssist business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Medical Device Sales (MyoSponge): Pre-commercial stage medical device company developing MyoSponge, an implantable scaffold for muscle regeneration. Revenue will be generated through direct sales of the medical device to healthcare providers (hospitals, surgical centers) for use in orthopedic trauma and reconstructive surgery procedures.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
GenAssist product offering
Product offeringCore offering
GenAssist is developing MyoSponge, an implantable biomaterial scaffold designed to mimic the Basal Lamina and treat Volumetric Muscle Loss (VML) by supporting stem cell-driven regeneration of functional skeletal muscle in orthopedic trauma and reconstructive surgery patients. The product is targeted at healthcare providers (hospitals and surgical centers) and is currently in pre-commercial development, with the scaffold made from FDA-cleared materials and protected by US Patent 11,744,922 B2.
Product overview
GenAssist is developing biomaterials for orthopedic trauma and reconstructive surgery. The company is working on MyoSponge, the first commercialized technology designed to rebuild strength after Volumetric Muscle Loss (VML). MyoSponge is a muscle-regenerating implantable scaffold that serves as the core product offering, designed to be implanted by surgeons to structurally support damaged muscle tissue and facilitate regeneration of functional muscle.
Differentiator
Problem solved
Functional benefit
Products and services
- MyoSponge A muscle-regenerating implantable scaffold designed to mimic the Basal Lamina (the native support structure that allows muscle cells to grow), targeting Volumetric Muscle Loss (VML) in orthopedic trauma and reconstructive surgery. The scaffold structurally supports damaged muscle tissue after necrotic tissue removal, enables patient stem cells to migrate, multiply, and mature into new muscle fibers, and then gradually resorbs and is replaced by functional muscle tissue. It is intended for implantation by orthopedic trauma and reconstructive surgeons at hospitals and surgical centers. The technology is protected by US Patent 11,744,922 B2.
Quantifiable outcome
- 46% muscle strength improvement
- +2 more outcomes
Companies that use GenAssist
Customer profileSegments1 record
Ideal customer profiles1 record
GenAssist technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
GenAssist partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Saint Louis UniversitycoreStrategic research partnership with Saint Louis University's Musculoskeletal Tissue Engineering Laboratory, led by Dr. Koyal Garg (Chief Discovery Officer). MyoSponge technology was invented at this academic institution, and the partnership provides ongoing scientific guidance, collaborative grant applications, and early-stage product research.
Scale indicators6 records
Recent moves5 records
Expansion highlights4 records
GenAssist competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
GenAssist social profiles
Digital presenceGenAssist financial estimates
Financial estimateRevenue estimate
Valuation estimate
GenAssist leadership team
Management profileNumber of profiles
Profiles4 records
GenAssist funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GenAssist M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GenAssist
What does GenAssist do?
GenAssist is developing MyoSponge, an implantable biomaterial scaffold designed to mimic the Basal Lamina and treat Volumetric Muscle Loss (VML) by supporting stem cell-driven regeneration of functional skeletal muscle in orthopedic trauma and reconstructive surgery patients. The product is targeted at healthcare providers (hospitals and surgical centers) and is currently in pre-commercial development, with the scaffold made from FDA-cleared materials and protected by US Patent 11,744,922 B2.
Is GenAssist a public or private company?
GenAssist is a private company. It is classified as venture growth investor backed and is currently operating.
When was GenAssist founded?
GenAssist was founded in 2019. It employs 1 to 10 people.
Where is GenAssist based?
GenAssist is headquartered in St Louis, United States, in the North America region.
How does GenAssist make money?
One revenue line is on record: medical Device Sales (MyoSponge).
Does GenAssist have an API?
No public API is recorded for GenAssist.
What industry is GenAssist in?
GenAssist's product category is Regenerative Medicine Implants. Its primary akta.pro industry code is HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials), with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 339113 and its SIC code is 3842.